This study will evaluate the efficacy and safety of irinotecan liposome(II) in combination with Ivonescimab as second line treatment for SCLC.
Age ≥18 years;
Histologically or cytologically confirmed SCLC;
Advanced SCLC who failed first-line platinum-based chemotherapy with or without checkpoint inhibitors;
The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;
Known allergy to irinotecan hydrochloride liposome injection (II) and eboxizumab or drug excipients
History of severe active autoimmune disease
Participated in other drug studies within 4 weeks before enrollment
Imaging during the screening period showed that the tumor surrounded important blood vessels or had significant necrosis and voids, and the investigators determined that entering the study would cause bleeding risk
The Second Affiliated Hospital of Dalian Medical University
Lead sponsor
Shengjing Hospital
Collaborator